EAACI Congress 2024

31 May - 03 June 2024 Valencia, Spain

OAS 6 - Frontiers in Allergen Immunotherapy: evidence from clinical trials

Friday 31 May, 15:00 PM - 16:30 PM Valencia, Spain
Granada Oral Abstract Sessions
15:00 001096
The SQ HDM SLIT-tablet improves QoL and reduces clinical symptoms in children (5-11 years) with house dust mite allergic rhinitis/rhinoconjunctivitis – results from a global phase III clinical trial
15:12 000243
Carry-over effect of 300 IR house dust mite sublingual immunotherapy tablet and relationship with disease activity: a post hoc analysis
15:24 001061
The SQ tree SLIT-tablet is effective and well-tolerated during the tree pollen season (birch homologous group) in children (5-17 years) – results from a global phase III clinical trial
15:36 001314
Intralymphatic immunotherapy of allergic rhinoconjunctivitis with grass allergoid microcrystalline tyrosine adsorbate produced reduced medication use and symptoms: a double-blind placebo-controlled trial
15:48 001330
Expansion of allergen-specific type 2 memory B cells with an altered phenotype after immunotherapy for bee venom or ryegrass pollen allergy
16:00 001402
Efficacy and safety of ALK 300 SRU 5-grass mix SLIT-drops in adults with grass pollen-induced rhinoconjunctivitis: results of the phase III trial RHAPSODY
16:12 001792
Predicting clinical response to allergen-specific immunotherapy to D. pteronyssinus using serological pre-treatment parameters